143 related articles for article (PubMed ID: 36924998)
1. Comparison of the AmpFire and MA-6000 polymerase chain reaction platforms for high-risk human papillomavirus testing in cervical precancer screening.
Effah K; Agbemafle I; Essel NO; Amuah JE; Kotey EN; Antwi-Boasiako E; Kemawor S; Gedzah I; Tekpor E; Wormenor CM; Atuguba BH; Danyo S; Akakpo PK
J Virol Methods; 2023 Jun; 316():114709. PubMed ID: 36924998
[TBL] [Abstract][Full Text] [Related]
2. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
[TBL] [Abstract][Full Text] [Related]
3. Evaluating operational parameters of the careHPV, GeneXpert, AmpFire, and MA-6000 HPV systems for cervical precancer screening: Experience from Battor, Ghana.
Effah K; Wormenor CM; Tekpor E; Amuah JE; Essel NOM; Gedzah I; Kemawor S; Hansen BT; Atuguba BH; Klutsey GB; Sesenu E; Danyo S; Akakpo PK
PLOS Glob Public Health; 2023; 3(8):e0001639. PubMed ID: 37624774
[TBL] [Abstract][Full Text] [Related]
4. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
[No Abstract] [Full Text] [Related]
5. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
6. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
7. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay.
Cho HW; Ouh YT; Hong JH; Min KJ; So KA; Kim TJ; Paik ES; Lee JW; Moon JH; Lee JK
J Virol Methods; 2019 Jul; 269():77-82. PubMed ID: 30998958
[TBL] [Abstract][Full Text] [Related]
8. Interest of human papillomavirus DNA quantification and genotyping in paired cervical and urine samples to detect cervical lesions.
Ducancelle A; Legrand MC; Pivert A; Veillon P; Le Guillou-Guillemette H; De Brux MA; Beby-Defaux A; Agius G; Hantz S; Alain S; Catala L; Descamps P; Postec E; Caly H; Charles-Pétillon F; Labrousse F; Lunel F; Payan C
Arch Gynecol Obstet; 2014 Aug; 290(2):299-308. PubMed ID: 24622934
[TBL] [Abstract][Full Text] [Related]
9. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
Marembo T; Dube Mandishora R; Borok M
Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
[TBL] [Abstract][Full Text] [Related]
10. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
11. Use of Fast Transfer Analysis Cartridges for Cervical Sampling and Real Time PCR Based High Risk HPV Testing in Cervical Cancer Prevention - a Feasibility Study from South India.
Vijayalakshmi R; Viveka TS; Malliga JS; Murugan K; Kanchana A; Arvind K
Asian Pac J Cancer Prev; 2015; 16(14):5993-9. PubMed ID: 26320486
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
13. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
14. Detection of human papillomavirus in fresh and dried urine through an automated system for cervical cancer screening in low- and middle-income countries.
Tanzi E; Bianchi S; Fappani C; Gori M; Colzani D; Passera I; Tincati C; Canuti M; Raviglione M; Amendola A
J Med Virol; 2023 May; 95(5):e28802. PubMed ID: 37219045
[TBL] [Abstract][Full Text] [Related]
15. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
Jung S; Lee B; Lee KN; Kim Y; Oh EJ
Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test.
Pista A; Verdasca N; Oliveira A
J Med Virol; 2011 Feb; 83(2):272-6. PubMed ID: 21181922
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance assessment of five human papillomavirus DNA tests using liquid-based cytology samples.
Song SH; Hong JH; Kwak SH; Lee JK; Kim MK
J Obstet Gynaecol Res; 2012 Feb; 38(2):408-14. PubMed ID: 22175246
[TBL] [Abstract][Full Text] [Related]
20. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer.
Senkomago V; Des Marais AC; Rahangdale L; Vibat CR; Erlander MG; Smith JS
J Clin Virol; 2016 Jan; 74():26-31. PubMed ID: 26655264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
